Group 1: Medical Device Registration - The company announced that its subsidiary, Shanghai Wanzijian Biotechnology Co., Ltd., and Healgen Scientific LLC have recently obtained medical device registration certificates in China, Australia, and Singapore [1] - The registration of these products enhances the variety of the company's flow cytometry technology platform and expands the market for respiratory triple detection products internationally [1] Group 2: Board of Directors Changes - The company reported the resignation of independent director Li Bo due to personal work reasons and has proposed Chen Junze as a candidate for the independent director position [4][5] - Chen Junze's qualifications and independence have been verified and will be submitted for shareholder approval [5][6] Group 3: Shareholder Meeting Notification - The company will hold its second extraordinary general meeting of 2025 on November 20, 2025, with both on-site and online voting options available [7][9] - The meeting will discuss various proposals that have been approved by the board and disclosed in previous announcements [12]

Core Viewpoint - The company, Dongfang Biological (688298), announced that its subsidiary, Shanghai Wanzijian Biotechnology Co., Ltd., and Healgen Scientific LLC have recently obtained medical device product registration certificates in China, Australia, and Singapore, enhancing the product variety of its flow fluorescence technology platform and expanding the international market for respiratory triple detection products [1]. Group 1 - The company has received medical device product registration certificates for multiple products [1] - The registration enhances the variety of products available on the company's flow fluorescence technology platform [1] - The respiratory triple detection products will help expand the company's international market presence [1]